Leap Therapeutics, Inc.

NasdaqCM LPTX

Leap Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: -77.73

Leap Therapeutics, Inc. Interest Coverage Ratio is -77.73 for the Trailing 12 Months (TTM) ending September 30, 2024, a 99.52% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Leap Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was -16,179.80, a -1,449.47% change year over year.
Leap Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -1,044.22, a -12.91% change year over year.
Leap Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -924.82, a -42.93% change year over year.
Leap Therapeutics, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -647.02, a 38.49% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

NasdaqCM: LPTX

Leap Therapeutics, Inc.

CEO	Mr. Douglas E. Onsi J.D.
IPO Date	Jan. 25, 2017
Location	United States
Headquarters	47 Thorndike Street
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years